• Georgina Gener, Montserrat Batlle, Mireia Morgades, María-José Jiménez, Christelle Ferrà, and Josep-Maria Ribera.
• Servicio de Hematología Clínica, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Institut de Recerca contra la Leucèmia, Josep Carreras, Barcelona, España. Electronic address: ggener@iconcologia.net.
• Med Clin (Barc). 2021 Oct 22; 157 (8): 380-384.

Background And PurposeGraft-versus-host disease (GVHD) and infections are complications after allogeneic stem cell transplantation (alloSCT). Anti-thymocyte globulin (ATG) is a strategy used as prophylaxis for GVHD. The study analyses the outcomes and frequency of infections with or without ATG after an unrelated donor alloSCT in patients with acute leukaemia and myelodysplastic syndrome.Patients And MethodsRetrospective study of patients receiving an unrelated donor alloSCT between December 2007 and April 2019. The main outcomes were analysed according to use or not of ATG.ResultsSixty-six patients were included. No significant differences were found between the ATG group (n=50) vs. no-ATG group (n=16) in overall survival, cumulative incidence of relapse, cumulative incidence of non-relapse mortality or cumulative incidence of acute GVHD or chronic GVHD. There was a greater frequency of infections in the ATG group (60 vs. 19%, P=.004).ConclusionsIn this study, no differences were shown in the main outcomes of alloSCT based on the use of ATG, although more infections were documented in the ATG group.Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

29 keywords...

hide…